These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The candidate, dubbed onvansertib, is being tested among patients with first-line RAS-mutated metastatic ... patients with non-small cell lung cancer and a genetic mutation dubbed KRAS G12C ...

Many cancers, including PDAC, are driven by mutations in the RAS family of oncogenes – genes that, when altered, promote cancer. Researchers have long sought drugs that target the actions of mutant ...

Historically, scientists in the division were the first to make the ground-breaking discovery of the mechanism by which the RAS gene – one of the most commonly activated genes in cancer – causes cells ...

While there is ongoing research to develop better tools like biochemical markers to differentiate fibrosis stage in MASH patients, the only standard currently used in MASH clinical studies involves ...

Black Diamond Therapeutics shows promise with BDTX-1535 for NSCLC treatment. Click here to find out why I rate BDTX stock a ...

These findings have important implications for congenital disorders, cancer, and aging ... Errors can occur when genetic material is copied, creating "unfit" cells that don't work properly.

Oncolytic viruses work by injecting genetic material into ... is planning a phase 2 trial of its RAS neoantigen vaccine TG01, targeting resected pancreatic cancer in combination with a checkpoint ...

And because BCL6 normally acts on 13 different apoptosis-promoting genes, the researchers ... that could target other cancer-driving proteins, including the oncogene Ras, which is a driver of ...

Weight loss drugs Bariatric surgery (weight loss surgery) Why is it so hard to lose weight and keep it off? Obesity is a ...

The KRAS gene is responsible for the production of a signaling protein called K-Ras. K-Ras tells cells how to divide, mature, and function. Dysregulation of this protein leads to uncontrolled cell ...

001), according to findings from a prespecified, exploratory analysis of the KEYNOTE-522 study (NCT03036488) in high-risk, early triple-negative breast cancer ... gene expression profile consensus ...